None listed
Conditions
Interventions
None listed
Sponsors
Pusan National University Yangsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patient diagnosed with essential hypertension and primary hypercholesterolemia, scheduled for treatment with a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe. 2.Patient diagnosed with essential hypertension or primary hypercholesterolemia, currently receiving treatment with antihypertensive or lipid-lowering medications, planning to switch to a combination medication containing amlodipine, losartan, rosuvastatin, and ezetimibe.
Exclusion criteria
Exclusion criteria: 1.According to the approval indications, the combination medication containing losartan and amlodipine should not be administered in cases where there are contraindications specified. 2.The statin class medications (such as rosuvastatin, atorvastatin) and ezetimibe should not be administered in cases where there are contraindications specified. 3.Patients with suspected secondary hyperlipidemia or secondary hyperlipidemia, such as nephrotic syndrome, proteinuria, obstructive liver disease, Cushing's syndrome, etc. 4.If the patient has received investigational drugs for clinical trials within 4 weeks prior to the registration date, or plans to participate in other clinical trials during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients whose blood pressure (Systolic Blood Pressure, SiSBP; Diastolic Blood Pressure, SiDBP) is controlled according to the target blood pressure guidelines of the '2018 Hypertension Treatment Guidelines' at 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The scores (or change in scores) of the Medication Satisfaction Questionnaire (MSQ), as assessed by patients at the 12-week time point. | — |
Countries
Korea, Republic of
Contacts
Public ContactMin ku Chon
Pusan National University Yangsan Hospital
Outcome results
None listed